DRDO’s anti-Covid drug 2-DG to be available at hospitals from June
The drug, named 2-deoxy-D-glucose (2-DG), has been developed jointly by Institute of Nuclear Medicine and Allied Sciences, a lab of the Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddy’s Laboratories, Hyderabad.
The Drugs Controller General of India (DCGI) earlier this month granted permission for emergency use of the drug as an adjunct therapy in moderate to severe Covid patients.
The Defence Research and Development Organisation’s 2-deoxy-D-glucose or ‘2-DG’ drug is the latest indigenous addition to India’s Covid-19 management efforts.
On May 1, the Drugs Controller General of India (DCGI) had cleared the formulation for emergency use as an adjunct therapy in moderate to severe Covid patients and the first batch of the homegrown anti-Covid drug was released on May 17 in the presence of Defence Minister Rajnath Singh and Health Minister Dr Harsh Vardhan.
The 2-DG has been developed by DRDO’s Institute of Nuclear Medicine and Allied Sciences (INMAS) in collaboration with Hyderabad-based pharmaceutical giant Dr Reddy’s Laboratories (DRL).